First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care?

McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N Engl J Med, 334, 1, 10.1056/NEJM199601043340101 Neijt, 1996, New therapy for ovarian cancer, N Engl J Med, 334, 50, 10.1056/NEJM199601043340112 Stuart, 1998, Updated analysis shows highly significant improved overall survival (OS) for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish intergroup trial, Proc Am Soc Clin Oncol, 17, 1394 Eisenhauer, 1994, European-Canadian randomised trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion, J Clin Oncol, 12, 2654, 10.1200/JCO.1994.12.12.2654 1990, 1133 du Bois, 1997, Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer, Ann Oncol, 8, 355, 10.1023/A:1008267419453 Bookmann, 1996, Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group, J Clin Oncol, 14, 1895, 10.1200/JCO.1996.14.6.1895 Huizing, 1997, Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer, J Clin Oncol, 15, 1953, 10.1200/JCO.1997.15.5.1953 ten Bokkel Huinink, 1997, Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer, Ann Oncol, 8, 351, 10.1023/A:1008219618331 Bolis, 1997, A phase I–II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer, Eur J Cancer, 33, 592, 10.1016/S0959-8049(96)00495-9 Siddiqui, 1997, A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer, Br J Cancer, 75, 287, 10.1038/bjc.1997.47 Lhommé, 1996, Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study, Semin Oncol, 23, 48 Calvert, 1989, Carboplatin dosage: Prospective evaluation of a simple formula based on renal function, J Clin Oncol, 17, 1748, 10.1200/JCO.1989.7.11.1748 Rowinsky, 1991, Sequence of Taxol and cisplatin: A phase I and pharmacologic study, J Clin Oncol, 9, 1692, 10.1200/JCO.1991.9.9.1692 Jeliffe, 1973, Creatinine clearance: Bedside estimate, Ann Intern Med, 79, 604, 10.7326/0003-4819-79-4-604 Neijt, 1998 du Bois, 1998, Cisplatin/paclitaxel vs carboplatin/paclitaxel as 1st-line treatment in ovarian cancer, Proc Am Soc Clin Oncol, 17, 1395 Ozols, 1997, Chemotherapy of advanced ovarian cancer: current status and future directions, Semin Oncol, 24, S2 Skarlos, 1997, Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study, Semin Oncol, 24, S15 Harper P. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date. Semin Oncol 24 (Suppl 15): S15–23 - S15–25 Aaronson, 1993, The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365 Mugia, 1997, Phase III of cisplatin or paclitaxel, versus their combination in suboptimal stage III and IV epithelial ovarian cancer: Gynecologic Oncology Group study # 132, Proc Am Soc Clin Oncol, 16, 1257 Alberts, 1992, Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III study randomised trial in stages III and IV ovarian cancer, J Clin Oncol, 10, 706, 10.1200/JCO.1992.10.5.706 Swenerton, 1992, Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomised phase III study of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 10, 718, 10.1200/JCO.1992.10.5.718 Gurney, 1990, Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma, Ann Oncol, 1, 427, 10.1093/oxfordjournals.annonc.a057796 Meerpohl, 1997, Randomised study comparing carboplatin/cyclophosphamide and cisplatin/ cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease, Gynecol Oncol, 66, 75, 10.1006/gyno.1997.4690 Edmonson, 1989, Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens, J Natl Cancer Inst, 81, 1500, 10.1093/jnci/81.19.1500 Taylor, 1994, Long-term follow-up of the first randomised study of cisplatin versus carboplatin for advanced ovarian cancer, J Clin Oncol, 12, 2066, 10.1200/JCO.1994.12.10.2066 ten Bokkel Huinink, 1988, Carboplatin in combination therapy for ovarian cancer, Cancer Treat Rev, 15, S9, 10.1016/0305-7372(88)90030-8 Conte, 1991, Carboplatin, Doxorubicin and Cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomised trial in stage III–IV epithelial ovarian carcinoma, J Clin Oncol, 9, 658, 10.1200/JCO.1991.9.4.658 Rowinsky, 1996, Meta analysis of paclitaxel (P) dose-response and dose-intensity (DI) in recurrent or refractory ovarian cancer (OC), Proc Am Soc Clin Oncol, 15, 288 Jakobsen, 1997, Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study, J Clin Oncol, 15, 193, 10.1200/JCO.1997.15.1.193 Gore, 1996, A randomised study of high versus standard dose carboplatin in patients (pts) with advanced epithelial ovarian cancer (EOC), Proc Am Soc Clin Oncol, 15, 769